Locus Cell Co., Ltd. (TPEX:6891)
Taiwan · Delayed Price · Currency is TWD 43.25
-2.55 (-5.57%)
Jul 16, 2026, 1:45 PM CST
Locus Cell Revenue
In the year 2025, Locus Cell had annual revenue of 12.74M TWD with 440.66% growth. Locus Cell had revenue of 9.28M in the half year ending December 31, 2025, with 2,186.70% growth.
Revenue
12.74M
Revenue Growth
+440.66%
P/S Ratio
675.30
Revenue / Employee
n/a
Employees
53
Market Cap
8.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.74M | 10.38M | 440.66% |
| Dec 31, 2024 | 2.36M | 1.95M | 480.30% |
| Dec 31, 2023 | 406.00K | -194.00K | -32.33% |
| Dec 31, 2022 | 600.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.39B |
| Adimmune | 1.41B |
| Savior Lifetec | 1.17B |
| PharmaEngine | 963.83M |
| Tanvex BioPharma | 483.94M |
| TaiGen Biopharmaceuticals Holdings | 258.93M |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |